Hospital change to mixed lipid emulsion from soybean oil-based lipid emulsion for parenteral nutrition in hospitalized and critically ill adults improves outcomes: a pre–post-comparative study

Table 3 Associations of 4-OLE with outcomes among all adults

	Intralipid*	4-OLE	Unadjusted analysis	Adjusted analysis
	(N = 341)	(N = 859)	p value	IRR (95% CI)	p-value
LOS, median (IQR)	22.2 (13.1–35.2)	20.3 (11.7–34.1)	0.28	0.97 (0.95, 0.99)	0.039

	Intralipid*	4-OLE	Unadjusted analysis	Adjusted analysis
	(N = 341) (%)	(N = 859) (%)	p value	OR (95% CI)	p-value
Hospital mortality	32 (9.38)	102 (11.87)	0.22	1.13 (0.72, 1.78)	0.6
30 day readmission	101 (29.62)	254 (29.57)	0.99	1.12 (0.83, 1.49)	0.46
90 day readmission	237 (69.50)	569 (66.24)	0.28	0.97 (0.73, 1.30)	0.85
Any infection	153 (44.87)	364 (42.37)	0.43	0.82 (0.63, 1.08)	0.16
Pneumonia	39 (11.44)	103 (11.99)	0.79	0.93 (0.61, 1.41)	0.73
UTI	33 (9.68)	62 (7.22)	0.15	0.69 (0.44, 1.10)	0.12

We adjusted for age, sex, race, ethnicity, insurance status, cancer, malnutrition, ED admission, ICU admission, and BMI in kg/m²
LOS Length of stay, IRR Incident rate ratio, OR Odds ratio, UTI Urinary tract infection, CI Confidence interval; 4-OLE SMOFLipid
^*Intralipid—(Baxter Inc, Deerfield, IL, USA)

ISSN: 1364-8535